Dianthus Therapeutics, Inc. DNTH
Regular-session close
After hours · Nov 20, 7:25 PM ET
- YTD
- +105.17%
- 1 year
- +109.33%
5D +1.44 (+1.64%)
- Market cap
- 4.76B
- Revenue (ttm)
- 2.72M
- EPS (ttm)
- -4.08
- Shares out
- 56.31M
- Forward P/E
- -19.83
- YTD return
- +105.17%
- 1-year return
- +109.33%
- 50-day average
- 86.81
- 200-day average
- 87.62
- Enterprise value
- 3.94B
- Volume
- 784.84K
- Avg volume
- 848.11K
- Open
- 83.62
- Previous close
- 84.83
- Day's range
- 82.58 – 85.67
- 52-week range
- 35.84 – 117.88
- Beta
- 0.26
- Analysts
- Strong Buy
- Price target
- 139.25 (+64.7%)
- Earnings date
- Mar 8, 2027
Key statistics
- Price / sales
- 1751.74
- Price / book
- 3.83
- Revenue growth
- 205.60%
- Free cash flow
- -109.14M
- Total cash
- 837.78M
- Total debt
- 1.21M
- Return on equity
- -22.61%
- Short % of float
- 18.89%
Fundamental scorecard
3 of 25 checks passed on DNTH’s reported financials
3of 25 checks passed
- Value 0 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Consensus: strong buy
- Target (low)
- 113.00
- Target (mean)
- 139.25
- Target (high)
- 200.00
- Strong buy1
- Buy17
- Hold0
- Sell0
- Strong sell0
Next earnings
Mar 8, 2027
Expected Mar 8, 2027. Consensus EPS estimate -0.96674.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Mar 8, 2027 | Dec 30, 2026 | -0.96 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.94454 | -0.81 | +0.13 | +14.24% |
| Aug 4, 2026 | Jun 30, 2026 | -0.84628 | -0.90 | -0.05 | -6.35% |
| May 5, 2026 | Mar 31, 2026 | -1.17 | -0.85 | +0.32 | +27.35% |
| Mar 9, 2026 | Dec 31, 2025 | -0.98 | -1.43 | -0.45 | -45.92% |
| Nov 5, 2025 | Sep 30, 2025 | -0.86 | -0.97 | -0.11 | -12.79% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Roth Capital | init | — | Buy |
| Oct 15, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 11, 2026 | JP Morgan | init | — | Overweight |
| Sep 4, 2026 | Citigroup | init | — | Buy |
| Aug 6, 2026 | Truist Securities | main | Buy | Buy |
| Aug 6, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- dianthustx.com
News
Dianthus Therapeutics, Inc. (DNTH) Presents at UBS Global Biopharma Conference 2026 Transcript
Dianthus Therapeutics (NASDAQ:DNTH) EVP Sells $9,118,555.02 in Stock
This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday Roth Capital Initiates Coverage On Dianthus Therapeutics with Buy Rating, Announces Price Target of $113
Your note
Sign in to keep a note on DNTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARR EDWARD | Officer | Sale | Mar 11, 2026 | 0 |
| GARCIA MARINO | Chief Executive Officer | Sale | Aug 6, 2026 | 65,292 |
| MCGEORGE ANNE | Director | Sale | Aug 9, 2026 | 0 |
| RANDHAWA SIMRAT | Officer | Sale | Aug 31, 2026 | 4,000 |
| READ SIMON J. | Director | Sale | Aug 18, 2026 | 0 |
| SAVITZ RYAN | Chief Financial Officer | Sale | Nov 11, 2026 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 15.19% | 8,552,759 | 723.14M | Sep 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 10.45% | 5,885,888 | 497.65M | Sep 29, 2026 |
| Blackrock Inc. | 7.80% | 4,389,604 | 371.14M | Sep 29, 2026 |
| Wellington Management Group, LLP | 5.34% | 3,006,167 | 254.17M | Sep 29, 2026 |
| Fairmount Funds Management LLC | 4.51% | 2,537,191 | 214.52M | Sep 29, 2026 |
| State Street Corporation | 4.50% | 2,534,458 | 214.29M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.93% | 1,649,920 | 139.50M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 2.83% | 1,592,149 | 134.62M | Sep 29, 2026 |
| VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 2.67% | 1,503,955 | 127.16M | Jul 30, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.45% | 1,380,523 | 116.72M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.17% | 1,224,305 | 103.51M | Sep 29, 2026 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 2.05% | 1,155,511 | 97.70M | Jun 29, 2026 |
